229 related articles for article (PubMed ID: 20702820)
1. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis.
Clement C; Capriotti JA; Kumar M; Hobden JA; Foster TP; Bhattacharjee PS; Thompson HW; Mahmud R; Liang B; Hill JM
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):339-44. PubMed ID: 20702820
[TBL] [Abstract][Full Text] [Related]
2. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis.
Pelletier JS; Stewart K; Trattler W; Ritterband DC; Braverman S; Samson CM; Liang B; Capriotti JA
Adv Ther; 2009 Aug; 26(8):776-83. PubMed ID: 19756415
[TBL] [Abstract][Full Text] [Related]
3. The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections.
Romanowski EG; Yates KA; Gordon YJ
Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5295-9. PubMed ID: 19516011
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of local ocular toxicity in candidate anti-adenoviral agents in vivo.
Inoue H; Sonoda KH; Ishikawa M; Kadonosono K; Uchio E
Ophthalmologica; 2009; 223(4):233-8. PubMed ID: 19262070
[TBL] [Abstract][Full Text] [Related]
5. Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model.
Romanowski EG; Araullo-Cruz T; Gordon YJ
Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):253-7. PubMed ID: 9019458
[TBL] [Abstract][Full Text] [Related]
6. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model.
Romanowski EG; Yates KA; Gordon YJ
Antiviral Res; 2001 Dec; 52(3):275-80. PubMed ID: 11675144
[TBL] [Abstract][Full Text] [Related]
7. The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir.
Kaneko H; Mori S; Suzuki O; Iida T; Shigeta S; Abe M; Ohno S; Aoki K; Suzutani T
Antiviral Res; 2004 Jan; 61(1):63-6. PubMed ID: 14670595
[TBL] [Abstract][Full Text] [Related]
8. Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study.
Kovalyuk N; Kaiserman I; Mimouni M; Cohen O; Levartovsky S; Sherbany H; Mandelboim M
Acta Ophthalmol; 2017 Dec; 95(8):e686-e692. PubMed ID: 28342227
[TBL] [Abstract][Full Text] [Related]
9. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model.
Romanowski EG; Gordon YJ; Araullo-Cruz T; Yates KA; Kinchington PR
Invest Ophthalmol Vis Sci; 2001 Jul; 42(8):1812-5. PubMed ID: 11431446
[TBL] [Abstract][Full Text] [Related]
10. N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model.
Romanowski EG; Yates KA; Teuchner B; Nagl M; Irschick EU; Gordon YJ
Invest Ophthalmol Vis Sci; 2006 May; 47(5):2021-6. PubMed ID: 16639011
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model.
de Oliveira CB; Stevenson D; LaBree L; McDonnell PJ; Trousdale MD
Antiviral Res; 1996 Jul; 31(3):165-72. PubMed ID: 8811201
[TBL] [Abstract][Full Text] [Related]
12. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis.
Pepose JS; Ahuja A; Liu W; Narvekar A; Haque R
Am J Ophthalmol; 2018 Oct; 194():7-15. PubMed ID: 29787732
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model.
Romanowski EG; Gordon YJ
Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):460-3. PubMed ID: 10670476
[TBL] [Abstract][Full Text] [Related]
14. Povidone iodine in the treatment of adenoviral conjunctivitis in infants.
Özen Tunay Z; Ozdemir O; Petricli IS
Cutan Ocul Toxicol; 2015 Mar; 34(1):12-5. PubMed ID: 24678746
[TBL] [Abstract][Full Text] [Related]
15. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study.
Hillenkamp J; Reinhard T; Ross RS; Böhringer D; Cartsburg O; Roggendorf M; De Clercq E; Godehardt E; Sundmacher R
Ophthalmology; 2002 May; 109(5):845-50. PubMed ID: 11986086
[TBL] [Abstract][Full Text] [Related]
16. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children.
Isenberg SJ; Apt L; Valenton M; Del Signore M; Cubillan L; Labrador MA; Chan P; Berman NG
Am J Ophthalmol; 2002 Nov; 134(5):681-8. PubMed ID: 12429243
[TBL] [Abstract][Full Text] [Related]
17. In Vitro efficacy of cyclosporine a and various antiseptics and antiviral drugs on adenovirus genotype 8, a common cause of epidemic keratoconjunctivitis.
Aydamirov AS; Harbiyeli II; Ozturk G; Yarkin F; Erdem E; Yagmur M
Int Ophthalmol; 2023 May; 43(5):1701-1710. PubMed ID: 36346478
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone/Povidone Eye Drops versus Artificial Tears for Treatment of Presumed Viral Conjunctivitis: A Randomized Clinical Trial.
Pinto RD; Lira RP; Abe RY; Zacchia RS; Felix JP; Pereira AV; Arieta CE; de Castro RS; Bonon SH
Curr Eye Res; 2015 Sep; 40(9):870-7. PubMed ID: 25310347
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment with topical 0.1% (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine inhibits adenovirus type 5 replication in the New Zealand rabbit ocular model.
Gordon YJ; Romanowski E; Araullo-Cruz T; De Clercq E
Cornea; 1992 Nov; 11(6):529-33. PubMed ID: 1334824
[TBL] [Abstract][Full Text] [Related]
20. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model.
Romanowski EG; Bartels SP; Gordon YJ
Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):378-84. PubMed ID: 9950596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
